Jeremy Docken

As I have stated previously, @GoodRx is a PBM scam, another form of spread pricing. Patients benefit from paying cash for some of the most often prescribed generic medications. There are far better options for patients to pay cash e.g., Costco #more" target="_blank" rel="nofollow noopener">drugchannels.net/2022/11/behind…

@A_Ciaccia When entering the health care space many years ago, I was told that the only sure business in pharma is to be a middleman. Wholesalers, GPOs, and PBMs are sweet deals if you can make one.

I bet there are some grumpy faces up in Dublin, Ohio this evening after reading this one. Ouch.

@A_Ciaccia I don't know about you, but it feels like there is so much change going on all at once that it is hard to know what to focus on.

Just when you thought we were catching up to the complexities of the healthcare delivery system…

Insurers and PBMs are Undermining Employee Health Benefits Employers have the power and they need to ensure that their employee drug benefits are protected from PBM/insurer profit-seeking practices @GHLForg @ppi @PioneerBoston healthcarebusinesstoday.com/insurers-and-p… via @HCBizToday

A timely reminder that #insulin #drug prices are not what they seem: "Understanding Insulin Prices" Do politicians understand that out-of-pocket costs, not list prices, are patients’ biggest challenge? @PioneerBoston @InsideSourcesDC #GrossToNetBubble drugch.nl/3xb8rPW

@340B_Report Wonderful pick! Looking forward to working with Emeka Egwim.

Breaking news: HRSA Picks Federal HIV/AIDS Policy Specialist Emeka Egwim To Be its Next #340B Program Director 340breport.com/hrsa-picks-fed…

Drug Channels News Roundup, January 2022 In this issue: - An update on the #GrossToNetBubble for #insulin - OptumRx trolls us - Patients vs. high-deductible health plans - #340B's unstoppable growth Plus: Fun with the CDC Read it all here ==> drugch.nl/3KHb8NR

@DrugChannels @pfizer @MedicaidBlog @FoleyHoag Brilliant work by Pfizer and their counsel.

Fascinating analysis of how @pfizer $PFE "warranty" program for XALKORI gets around #Medicaid best price risks Spoiler: An insurer warranties the drug and pays any refunds/rebates to a patient or plan. Clever. drugch.nl/3lKKg4Z @MedicaidBlog @FoleyHoag

Dear Lawmakers @POTUS @RonWyden @SpeakerPelosi Hundreds of us biotech investors, innovators, patient advocates, & NIH academics representing >40k US jobs, >600 drugs in trials, & >$200B invested propose solutions to affordability that preserve R&D. 1/ nopatientleftbehind.docsend.com/view/a6bxibzxy…

The cost of drugs has long been a hot-button topic, but how might the landscape be changing for 2021? The Current State of Drug Pricing and Forecasts for the Future explores what drug makers need to know as the Biden administration tackles #drugpricing ➡️pharmexec.com/view/the-curre…

@johncutlefish This is why I never wanted to become a product manager!

@DrugChannels @bobjherman @axios @amazon Also nice to see you quoted, Adam. ;-)

Good one from @bobjherman @axios : A reality check on @amazon's $AMZN rumored pharmacy stores drugch.nl/2RRaVAX

@DrugChannels Sadly our approach to healthcare is finding a villain to blame and fight against because it's easier to score political points vs solving the actual problem, which is harder and involves some pain and compromise.

It’s hard to have sensible policy conversations about "#drug pricing” when politicians won't or can't distinguish between: 1. A drug's list price 2. A drug's net cost to a payer/#PBM after rebates & discounts 3. The % of a prescription's net cost that a patient pays out-of-pocket

R.I.P., #rebate rule @HHSGov delays world w/o rebates until at least 2023, due to @pcmanet lawsuit: drugch.nl/3oBokHV Good news for #PBMs & #GrossToNetBubble ; Bad news for patients taking deeply-discounted #drugs 😔 My still-relevant 2019 $0.02: drugch.nl/2WSR83k

Questions: What happens to patients whose medication is no longer covered by the PBM? Do insurers who now supposedly own these PBMs care about the total cost of care due to poor outcomes? Answers: WHO CARES & NO since rebate contracting driving this behavior is far more lucrative

PCMA will always protect the rebate contracting gravy train, as it is the most lucrative part of the RX benefit management & AARP opposing the rebate rule is because AARP is a PBM & not a patient group as advertised read👇 hsj.gr/medicine/refor… fiercehealthcare.com/payer/pcma-sue…

Great paper showing why HHS's "world without rebates" Part D rule is good policy for directing drug discounts where they matter-to reduce patient OOP spend.

Curious about others’ reactions to my belief that @ONC_HealthIT's info blocking rule is a really, really big deal. As in, perhaps more so than anything in the previous or next 5 years. forbes.com/sites/sethjose…

Only in 340B is margin and profit called "savings"